Muhammad Adnan Khattak

Author

Edith Cowan University

Also Known As

Muhammad Adnan Khan Khattak, Muhammad Adnan Khattak, Shu-Kui Qin

Publications

574

Citations

H-Index

Concepts

All Affiliations

Edith Cowan University The University of Western Australia Fiona Stanley Hospital Melanoma Institute Australia Sir Charles Gairdner Hospital

About

Muhammad Adnan Khattak is an author at Edith Cowan University specializing in oncology, cancer therapeutics, and molecular oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	116
2	Pathology	4	4	116
3	Immunology	3	3	59
4	Surgical Oncology	1	1	16
5	Cancer Cell Biology	1	1	28

Muhammad Adnan Khattak

Publications

437

Citations

H-Index

Page 1

	Year	Citations
Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study Naomi Wright, Andrew Leather, Niyi Ade‐Ajayi, The Lancet	2021	162
Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells Carlos Aya‐Bonilla, Michael Morici, Xin Hong, British Journal of Cancer	2020	58
Ipilimumab activity in advanced uveal melanoma Muhammad Adnan Khattak, Rosalie Fisher, Peta Hughes, Melanoma Research Tumor BiologySkin CancerMedicinePhotocarcinogenesisMelanoma	2012	57
Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy Afaf Abed, Leslie Calapre, Johnny Lo, Journal for ImmunoTherapy of Cancer	2020	50
Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial. Jeffrey S. Weber, Muhammad Adnan Khattak, Matteo S. Carlino, Journal of Clinical Oncology ImmunologyPathologyResected MelanomaCancer BiologyNeoantigen Therapy Mrna-4157	2024	28
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401 Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, Journal of Clinical Oncology	2023	23
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. Jason J. Luke, Paolo A. Ascierto, Muhammad Adnan Khattak, Journal of Clinical Oncology Surgical OncologyCancer ManagementImmunologyPathologyDistant Metastasis-free Survival	2023	16
Cancer services in <scp>W</scp>estern <scp>A</scp>ustralia: A comparison of regional outcomes with metropolitan <scp>P</scp>erth Hilary Martin, Kanako Ohara, Wee Chin, Australian Journal of Rural Health	2015	15
Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma. Melissa Eastgate, Victoria Atkinson, Muhammad Adnan Khattak, Journal of Clinical Oncology ImmunologyImmunoeditingPathologyImmunotherapyEftilagimod Alpha	2018	15
INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma. Jeffrey S. Weber, Jason J. Luke, Matteo S. Carlino, Journal of Clinical Oncology	2024	13

Page 1